Ongoing Task Forces

- Immunopharmacology: small molecule-based therapies in allergy and clinical immunology

Chronic airway diseases such as asthma and COPD and their comorbidities bear a significant burden on public health, which makes it necessary to translate the fast expanding insights gained of the molecular networks underlying inflammatory airway disease into new therapies, in particular for distinct phenotypes not controlled by current treatment regimens. The aim of this taskforce is to compare the distinct pharmacological properties and clinical applications of small molecule- and antibody-based treatment strategies already in clinical use or under clinical or preclinical evaluation, compare their specific limitations and challenges and highlight how their therapeutic integration should be better exploited to fill the critical gaps in current treatment for chronic inflammatory respiratory diseases.

Please find the list of all members of this task force here.
Last updated 08 June 2018
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel